TY - JOUR
TI - Beta Blockers and Chronic Obstructive Pulmonary Disease (COPD): Sum of Evidence
AU - Baou, K.
AU - Katsi, V.
AU - Makris, T.
AU - Tousoulis, D.
JO - Current Hypertension Reviews
PY - 2021
VL - 17
TODO - 3
SP - 196-206
PB - Bentham Science Publishers
SN - 1573-4021
TODO - 10.2174/1573402116999201209203250
TODO - acebutolol;  atenolol;  beta adrenergic receptor blocking agent;  betaxolol;  bisoprolol fumarate;  carvedilol;  esmolol;  labetalol;  metoprolol;  nadolol;  nebivolol;  penbutolol;  pindolol;  propranolol;  sotalol;  timolol;  beta adrenergic receptor blocking agent, all cause mortality;  angina pectoris;  atrial fibrillation;  cardiovascular disease;  cardiovascular mortality;  chronic obstructive lung disease;  coronary artery bypass graft;  forced expiratory volume;  heart failure;  heart infarction;  heart ventricle arrhythmia;  hypertension;  lung disease;  lung function;  migraine;  respiratory tract disease;  Review;  cardiovascular disease;  chronic obstructive lung disease;  heart arrhythmia;  heart failure;  human, Adrenergic beta-Antagonists;  Arrhythmias, Cardiac;  Cardiovascular Diseases;  Heart Failure;  Humans;  Pulmonary Disease, Chronic Obstructive
TODO - Approximately half a century has passed since the discovery of beta-blockers. Then, their prime therapeutic purpose was to treat angina and cardiac arrhythmias; nowadays, beta-blockers’ usage and effectiveness are extended to treat other cardiovascular diseases, such as hypertension, congestive heart failure, and coronary artery disease. Safety concerns were raised about beta-blockers and their use for chronic obstructive pulmonary disease (COPD) patients with concurrent cardiovascular disease. After thorough research of the literature, this review summarizes the evidence proving that beta-blockers not only might be well tolerated in COPD patients, but they might also have a beneficial effect in this group of patients. © 2021 Bentham Science Publishers.
ER -